




RealRate

PHARMACEUTICAL 2017

Traverse Therapeutics Inc
Rank 137 of 308



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of Traverse Therapeutics Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Traverse Therapeutics Inc compared to the market average is the variable Intangible Assets, increasing the Economic Capital Ratio by 43% points. The greatest weakness of Traverse Therapeutics Inc is the variable Other Liabilities, reducing the Economic Capital Ratio by 52% points.

The company's Economic Capital Ratio, given in the ranking table, is 280%, being 36% points above the market average of 245%.

Input Variable	Value in 1000 USD	Output Variable	Value in 1000 USD
Assets, Current	332,352	Assets	525,282
Cost of Goods Sold	0	Liabilities	217,515
Intangible Assets	182,979	Expenses	182,126
Liabilities, Current	83,262	Revenues	133,591
Liabilities, Non-Current	4,010	Stockholders Equity	307,767
Other Assets	7,364	Net Income	-47,903
Other Compr. Net Income	192	Comprehensive Net Income	-47,807
Other Expenses	18,470	BaseVar	529,669
Other Liabilities	130,243	ECR before Limited Liability	168%
Other Net Income	632	Economic Capital Ratio	280%
Other Revenues	133,591		
Property and Equipment	2,587		
Research and Development	70,853		
Selling, General and Administrative Expense	92,803		